Publications
2023
Weaver DF. Amyloid-β is a cytokine. Alzheimers Dement. 2023 May 25. doi: 10.1002/alz.13165. Epub ahead of print. PMID: 37228244.
Oh M, Weaver DF. Alzheimer’s disease as a fundamental disease of information processing systems: An information theory perspective. Front Neurosci. 2023 Feb 10;17:1106623. doi: 10.3389/fnins.2023.1106623. PMID: 36845437; PMCID: PMC9950401.
Oh M, Weaver DF. Alzheimer’s disease as a fundamental disease of information processing systems: An information theory perspective. Front Neurosci. 2023 Feb 10;17:1106623. doi: 10.3389/fnins.2023.1106623. PMID: 36845437; PMCID: PMC9950401.
Weaver DF. The Immunopathy of Alzheimer’s Disease: Innate or Adaptive? Curr Alzheimer Res. 2023 May 17. doi: 10.2174/1567205020666230517103312. Epub ahead of print. PMID: 37198985.
2022
Wang Z, Weaver DF. Microglia and microglial-based receptors in the pathogenesis and treatment of Alzheimer’s disease. Int Immunopharmacol. 2022 Sep;110:109070. doi: 10.1016/j.intimp.2022.109070. Epub 2022 Jul 21. PMID: 35978514.
Weaver DF. Alzheimer’s disease as an innate autoimmune disease (AD2 ): A new molecular paradigm. Alzheimers Dement. 2022 Sep 27. doi: 10.1002/alz.12789. Epub ahead of print. PMID: 36165334.
DeBay DR, Phi TT, Bowen CV, Burrell SC, Darvesh S. No difference in cerebral perfusion between the wild-type and the 5XFAD mouse model of Alzheimer’s disease. Sci Rep. 2022 Dec 22;12(1):22174. doi: 10.1038/s41598-022-26713-x. PMID: 36550188; PMCID: PMC9780330.
Maxwell SP, Cash MK, Darvesh S. Neuropathology and cholinesterase expression in the brains of octogenarians and older. Chem Biol Interact. 2022 Sep 1;364:110065. doi: 10.1016/j.cbi.2022.110065. Epub 2022 Jul 21. PMID: 35872043.
Meier-Stephenson FS, Meier-Stephenson VC, Carter MD, Meek AR, Wang Y, Pan L, Chen Q, Jacobo S, Wu F, Lu E, Simms GA, Fisher L, McGrath AJ, Fermo V, Barden CJ, Clair HDS, Galloway TN, Yadav A, Campágna-Slater V, Hadden M, Reed M, Taylor M, Kelly B, Diez-Cecilia E, Kolaj I, Santos C, Liyanage I, Sweeting B, Stafford P, Boudreau R, Reid GA, Noyce RS, Stevens L, Staniszewski A, Zhang H, Murty MRVS, Lemaire P, Chardonnet S, Richardson CD, Gabelica V, DePauw E, Brown R, Darvesh S, Arancio O, Weaver DF. Alzheimer’s disease as an autoimmune disorder of innate immunity endogenously modulated by tryptophan metabolites. Alzheimers Dement (N Y). 2022 Apr 6;8(1):e12283. doi: 10.1002/trc2.12283. PMID: 35415204; PMCID: PMC8985489.
Gupta M, Weaver DF. Alzheimer’s: The ABCDE Paradigm. ACS Chem Neurosci. 2022 May 4;13(9):1355-1357. doi: 10.1021/acschemneuro.2c00195. Epub 2022 Apr 15. PMID: 35427106.
2021
Zheng Y, Stafford PM, Stover KR, Mohan DC, Gupta M, Keke EC, Schiavini P, Villar L, Wu F, Kreft A, Thomas K, Raaphorst E, Pasangulapati JP, Alla SR, Sharma S, Mittapalli RR, Sagamanova I, Johnson SL, Reed MA, Weaver DF. A Series of 2-((1-Phenyl-1H-imidazol-5-yl)methyl)-1H-indoles as Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. ChemMedChem. 2021 Mar 23. doi: 10.1002/cmdc.202100107. Epub ahead of print. PMID: 33759400.
Wang Z, Wang Y, Pasangulapati JP, Stover KR, Liu X, Schier SW, Weaver DF. Design, synthesis, and biological evaluation of furosemide analogs as therapeutics for the proteopathy and immunopathy of Alzheimer’s disease. Eur J Med Chem. 2021 Jun 2;222:113565. doi: 10.1016/j.ejmech.2021.113565. Epub ahead of print. PMID: 34118718.
Mancini RS, Barden CJ, Weaver DF, Reed MA. Furazans in Medicinal Chemistry. J Med Chem. 2021 Feb 25;64(4):1786-1815. doi: 10.1021/acs.jmedchem.0c01901. Epub 2021 Feb 11. PMID: 33569941.
Katrina L. Forrestall, Darcy E. Burley, Meghan K. Cash, Ian R. Pottie, and Sultan Darvesh. Phenothiazines as dual inhibitors of SARS-CoV-2 main protease and COVID-19 inflammation. Canadian Journal of Chemistry. e-First. doi:10.1139/cjc-2021-0139.
2020
Katrina L. Forrestall, Darcy E. Burle , Meghan K. Cash, Ian R. Pottie, Sultan Darvesh. 2-Pyridone Natural Products as Inhibitors of SARS-CoV-2 Main Protease. Chem Biol Interact. 2021 Feb 1;335:109348. doi: 10.1016/j.cbi.2020.109348. Epub 2020 Dec 2. PMID: 33278462 PMCID: PMC7710351
O’Leary TP, Mantolino HM, Stover K, Darvesh S, Brown RE. 2020. Intact olfactory memory in the 5XFAD mouse model of Alzheimer’s disease from 3 to 15 months of age. Behavioural Brain Research. 393: 112731. PMID: 32522622.
Brennecke A, Villar L, Wang Z, Doyle LM, Meek A, Reed M, Barden C, Weaver DF. Is Inhaled Furosemide a Potential Therapeutic for COVID-19? Am J Med Sci. 2020 Sep;360(3):216-221. doi: 10.1016/j.amjms.2020.05.044. Epub 2020 Jun 1. PMID: 32622469.
Gupta M, Bogdanowicz T, Reed MA, Barden CJ, Weaver DF. The Brain Exposure Efficiency (BEE) Score. ACS Chem Neurosci. 2020 Jan 15;11(2):205-224. doi: 10.1021/acschemneuro.9b00650. Epub 2019 Dec 27. PMID: 31815431.
Wang Z, Wang Y, Vilekar P, Yang SP, Gupta M, Oh MI, Meek A, Doyle L, Villar L, Brennecke A, Liyanage I, Reed M, Barden C, Weaver DF. Small molecule therapeutics for COVID-19: repurposing of inhaled furosemide. PeerJ. 2020 Jul 7;8:e9533. doi: 10.7717/peerj.9533. PMID: 32704455; PMCID: PMC7350920.
2019
Bose P, Tremblay E, Maois C, Narasimhan V, Armstrong GAB, Liao M, Parker JA, Robitaille R, Wen XY, Barden C, Drapeau P. The Novel Small Molecule TRVA242 Stabilizes Neuromuscular Junction Defects in Multiple Animal Models of Amyotrophic Lateral Sclerosis. Neurotherapeutics. 2019 Oct;16(4):1149-1166. doi: 10.1007/s13311-019-00765-w. PMID: 31342410; PMCID: PMC6985319.
Fertan E, Stover KRJ, Brant MG, Stafford PM, Kelly B, Diez-Cecilia E, Wong AA, Weaver DF, Brown RE. Effects of the Novel IDO Inhibitor DWG-1036 on the Behavior of Male and Female 3xTg-AD Mice. Front Pharmacol. 2019 Sep 24;10:1044. doi: 10.3389/fphar.2019.01044. PMID: 31607909; PMCID: PMC6773979.
Gupta M, Lee HJ, Barden CJ, Weaver DF. The Blood-Brain Barrier (BBB) Score. J Med Chem. 2019 Nov 14;62(21):9824-9836. doi: 10.1021/acs.jmedchem.9b01220. Epub 2019 Oct 25. PMID: 31603678.
Liyanage SI, Weaver DF. Misfolded proteins as a therapeutic target in Alzheimer’s disease. Adv Protein Chem Struct Biol. 2019;118:371-411. doi: 10.1016/bs.apcsb.2019.08.003. Epub 2019 Sep 21. PMID: 31928732.
2018
Brant MG, Goodwin-Tindall J, Stover KR, Stafford PM, Wu F, Meek AR, Schiavini P, Wohnig S, Weaver DF. Identification of Potent Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors Based on a Phenylimidazole Scaffold. ACS Med Chem Lett. 2018 Jan 11;9(2):131-136. doi: 10.1021/acsmedchemlett.7b00488. PMID: 29456801; PMCID: PMC5807880.
Kolaj I, Imindu Liyanage S, Weaver DF. Phenylpropanoids and Alzheimer’s disease: A potential therapeutic platform. Neurochem Int. 2018 Nov;120:99-111. doi: 10.1016/j.neuint.2018.08.001. Epub 2018 Aug 8. PMID: 30098379.
Liyanage SI, Santos C, Weaver DF. The hidden variables problem in Alzheimer’s disease clinical trial design. Alzheimers Dement (N Y). 2018 Nov 13;4:628-635. doi: 10.1016/j.trci.2018.09.003. PMID: 30519628; PMCID: PMC6260222.
Mancini RS, Wang Y, Weaver DF. Phenylindanes in Brewed Coffee Inhibit Amyloid-Beta and Tau Aggregation. Front Neurosci. 2018 Oct 12;12:735. doi: 10.3389/fnins.2018.00735. PMID: 30369868; PMCID: PMC6194148.
Metaxas A, Thygesen C, Kempf SJ, Anzalone M, Vaitheeswaran R, Petersen S, Landau AM, Audrain H, Teeling JL, Darvesh S, Brooks DJ, Larsen MR, Finsen B. 2018. Tauopathy in the APPswe/PS1ΔE9 mouse model of familial Alzheimer’s disease. bioRxiv. 405647.
Metaxas A, Thygesen C, Kempf SJ, Anzalone M, Vaitheeswaran R, Petersen S, Landau AM, Audrain H, Teeling JL, Darvesh S, Brooks DJ, Larsen MR, Finsen B. 2018. Tauopathy in the APPswe/PS1ΔE9 mouse model of familial Alzheimer’s disease. bioRxiv. 405647.